Mandate

Vinge has advised VEF Ltd in connection with a directed share issue

November 19, 2020 Capital Markets and Public M&A

Vinge has advised VEF Ltd, an investment company whose Swedish Depositary Receipts (“SDR”) are listed on Nasdaq First North, in connection with a directed share issue whereby VEF receives approximately SEK 522 million in issue proceeds.

The subscription price was determined to SEK 3.15 per SDR through an accelerated book building process. The share issue was directed to selected Swedish and international investors. The company intends to use the expected net proceeds from the transaction to enable potential near-term investment opportunities.

VEF Ltd is an investment company that invests in growth stage private fintech companies. VEF focuses on scale emerging markets and invests across all areas of financial services inclusive of payments, credit, mobile money and wealth advisors. VEF trades in Sweden on Nasdaq First North Growth Market under the ticker VEFL SDB.

Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg and Eléonore Friberg.

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025